Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effectiveness of Topical Glycerine Sulphate Paste, Hirudoid Cream and Nil Application on Superficial Phlebitis

This study has been completed.
Information provided by:
Tan Tock Seng Hospital Identifier:
First received: October 20, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted
The aim of the interventional study is to compare the different treatment modalities in reducing erythema size and rate of resolving phlebitis.

Condition Intervention
Drug: Glycerine Magnesium sulphate paste
Drug: Mucopolysaccharide polysulphate
Other: No application

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: To Investigate the Effectiveness of Topical Glycerine Sulphate, Hirudoid Cream and Nil Application in Treating Peripheral Cannula Related Phlebitis

Resource links provided by NLM:

Further study details as provided by Tan Tock Seng Hospital:

Primary Outcome Measures:
  • Erythema size [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]
    The incremental percentage change in erythema size

Secondary Outcome Measures:
  • Time to resolve redness [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]
    The rate of phlebitis resolution

Enrollment: 147
Study Start Date: November 2009
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Glycerine Magnesium Sulphate paste Drug: Glycerine Magnesium sulphate paste
Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
Active Comparator: Hirudoid cream
Topical Mucopolysaccharide polysulphate
Drug: Mucopolysaccharide polysulphate
Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
Experimental: No application
Patient will not receive any topical application to apply on the phlebitis site. The outcome assessor will monitor regularly at pre-determined schedule as patients in other active arms.
Other: No application
No application


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients admitted to the study institution between Dec 2009 and Feb 2010 and observed to develop redness associated with peripheral infusion cannula.

Exclusion Criteria:

  • Thrombosis, poor skin condition, and pus seen at the previous puncture.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01226069

Tan Tock Seng Hospital
Singapore, Singapore, 308433
Sponsors and Collaborators
Tan Tock Seng Hospital
Principal Investigator: Isabel Ng, MSc Epidemiology Tan Tock Seng Hospital
  More Information

Responsible Party: Isabel Ng Hui Leng, Tan Tock Seng Hospital Identifier: NCT01226069     History of Changes
Other Study ID Numbers: D/09/481 
Study First Received: October 20, 2010
Last Updated: October 20, 2010
Health Authority: Singapore: Domain Specific Review Boards
Singapore: Health Sciences Authority

Keywords provided by Tan Tock Seng Hospital:
superficial phlebitis
cannula-related vein inflammation
Glycerine magnesium sulphate
Hirudoid cream

Additional relevant MeSH terms:
Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases
Magnesium Sulfate
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Tocolytic Agents
Reproductive Control Agents
Cryoprotective Agents
Protective Agents processed this record on October 21, 2016